Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan.

Tada, Yayoi; Soliman, Ahmed M; Ishii, Kanako; Sakuma, Ryuta; Puig, Luis; Davis, Matthew; Nunag, Dominic; Pinter, Andreas; Imafuku, Shinichi

Tada, Yayoi; Soliman, Ahmed M; Ishii, Kanako; Sakuma, Ryuta; Puig, Luis; Davis, Matthew; Nunag, Dominic; Pinter, Andreas; Imafuku, Shinichi.

Afiliação

Tada Y; Teikyo University School of Medicine, Tokyo, Japan.
Soliman AM; AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA. ahmed.m.soliman@abbvie.com.
Ishii K; AbbVie GK, Tokyo, Japan.
Sakuma R; AbbVie GK, Tokyo, Japan.
Puig L; Department of Dermatology, IIB SANTPAU, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Carrer de Sant Quintí, 89, 08041, Barcelona, Spain.
Davis M; Medicus Economics, LLC, Milton, MA, USA.
Nunag D; Medicus Economics, LLC, Milton, MA, USA.
Pinter A; Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Imafuku S; Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan.

Dermatol Ther (Heidelb) ; 14(1): 99-114, 2024 Jan.

Article em En | MEDLINE | ID: mdl-38019410

Palavras-chave

Biologics; Discontinuation; Interleukin inhibitors; Japan; Persistence; Psoriasis; Switching; Treatment patterns

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Dermatol Ther (Heidelb) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google